Aurobindo Pharma has received its board approval to raise up to an amount of $350 million through issue shares to Qualified Institutional Buyers. The approval to issue shares under Qualified Institutional Placement (QIP) was secured at a meeting held on January 21, 2015.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1676.00 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1235.05 |
| Zydus Lifesciences | 941.20 |
| Lupin | 2330.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: